Mineralys Therapeutics (MLYS) In Focus As Lorundrostat Data Nears Fair Value Debate

Mineralys Therapeutics (MLYS) is back in focus after the company announced that new long term efficacy and safety data for its hypertension drug candidate lorundrostat will be spotlighted at the American Heart Association Scientific Sessions 2026.

Mineralys Therapeutics shares have been under pressure, with the 1-day share price return down 2.75% and the year to date share price return down 27.58%. The 3-year total shareholder return of 171.92% still reflects a very strong earlier rerating that recent weakness has started to cool.

Scan for other hypertension and cardiorenal players at a similar inflection point by checking our curated list of list of solid balance sheet and fundamentals (24 results)

Mineralys Therapeutics has slipped on fresh data headlines, so some investors may be inclined to wait for a cleaner entry. The key question is whether today’s reset already reflects the risks that appear in the valuation work that follows.

Most Popular Narrative: 47% Undervalued

Mineralys Therapeutics is trading at $25.86 against a most-followed fair value of $48.50. The valuation narrative leans heavily on lorundrostat turning a pre-revenue biotech into a commercial story over time.

Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

See why 4 investors see Mineralys Therapeutics as 47% undervalued.

Result: Fair Value of $48.50 (UNDERVALUED)

Still, the entire Mineralys Therapeutics story leans on lorundrostat clearing the NDA process and avoiding heavier than expected competition that could blunt uptake and pricing power.

Find out about the key risks to this Mineralys Therapeutics narrative.

Another Way To Look At Mineralys Therapeutics

The first take leans on analyst targets and future earnings. A second lens uses current P/B. Mineralys Therapeutics trades at 4.1x book value, compared with 2.1x for the broader US Biotechs group and 4.5x for closer peers, so valuation risk skews more towards expectations than clear consensus. Which side of that trade do you trust more?

For a closer look at what today’s P/B might imply if sentiment or fundamentals shift, it is worth asking how far that gap could stretch or compress relative to peers before the market blinks, See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed messages on Mineralys Therapeutics so far. With both risk flags and upside angles in play, move quickly and build your own thesis by weighing 2 key rewards and 2 important warning signs.

Looking for more Mineralys Therapeutics sized ideas?

If you want Mineralys Therapeutics to be just one part of a stronger watchlist, use the screener to spot other setups before the crowd moves.

• Target more dependable payers by reviewing 8 dividend fortresses, built around companies that combine higher yields with balance sheets that aim to support ongoing distributions.
• Hunt for mispriced opportunities by scanning 16 high quality undiscovered gems, which pair solid fundamentals with lower visibility and potential room for sentiment to catch up.
• Prioritise resilience first by filtering through 30 resilient stocks with low risk scores, focused on businesses with stronger financial profiles designed to hold up across different conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com